Market Overview:
The global genomics biomarkers market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of chronic diseases, technological advancements in genomics biomarkers, and rising demand for personalized medicine. Based on type, the global genomics biomarkers market is segmented into oncology, cardiovascular diseases, and neurological diseases. The oncology segment is expected to account for the largest share of the global genomics biomarkers market in 2018. This can be attributed to increasing incidence of cancer and growing demand for targeted therapies. Based on application, the global genomics biomarkers market is segmented into diagnostic and research laboratories and hospitals.
Product Definition:
Genomics biomarkers are DNA or RNA sequences that indicate the presence of a particular disease or condition. They can be used to diagnose a disease, monitor its progress, and predict its outcome. Genomics biomarkers are important because they can help doctors to diagnose diseases earlier and more accurately, which can lead to better treatment outcomes.
Oncology:
Oncology is the study of cancer, a disease in which cells in the body multiply and develop into abnormal cells that can spread to other parts of the body. Oncology also includes treatment for cancer. Cancer is classified as either benign or malignant based on its behavior (its tendency or appearance) during development.
Cardiovascular Diseases:
Cardiovascular diseases (CVD) is a group of conditions that involve the heart and blood vessels. It can be caused by genetic, lifestyle, or environmental factors. The most common types of CVDs are coronary heart disease (CHD), stroke, and peripheral artery disease. According to WHO statistics in 2015; 17 million people died from CVDs which accounts for 31% deaths globally or 9% of all deaths worldwide.
Application Insights:
The diagnostic and research laboratories segment dominated the global market in 2017. This can be attributed to the rising prevalence of chronic diseases, such as cancer, infectious diseases, and neurological disorders. Moreover, increasing government funding for genomic research is expected to boost product demand in this segment over the forecast period.
Infectious disease testing accounted for a significant share in 2017 owing to an increase in number of genetic variants associated with infectious diseases susceptibility. For instance, more than 20 million people are estimated to be infected with HIV worldwide according to UNAIDS estimates published in December 2016. However, only 1% of these individuals are estimated to access antiretroviral therapy (ART), which leads towards high unmet needs regarding diagnosis of AIDS across various regions globally.
Regional Analysis:
North America dominated the global genomics biomarkers market in 2016. This can be attributed to the presence of key players, increased government funding for genomic studies, and high prevalence of chronic diseases in this region. For instance, as per a recent study published by National Cancer Institute (NCI), around 60% of all cancer deaths could be prevented if people had regular check-ups for cancer detection at an early stage. Moreover, increasing efforts from public and private entities to develop cost-effective diagnostic tests are expected to boost revenue growth over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising healthcare expenditure coupled with growing awareness about early diagnosis among patients suffering from common diseases such as cardiovascular disorders and neurological conditions like Alzheimer’s disease & Parkinson's disease & Huntington’s disease etc., which leads them being diagnosed at a late stage when treatment becomes more expensive than treating it at an early stage would have been.
Growth Factors:
- Increasing demand for personalized medicines
- Rising prevalence of chronic diseases
- Growing investments in genomics research
- Advances in genomic sequencing technology
- Proliferation of precision medicine initiatives
Scope Of The Report
Report Attributes
Report Details
Report Title
Genomics Biomarkers Market Research Report
By Type
Oncology, Cardiovascular Diseases, Neurological Diseases
By Application
Diagnostic and Research Laboratories, Hospitals
By Companies
Roche Diagnostics, Myriad Genetics, QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Genomics Biomarkers Market Report Segments:
The global Genomics Biomarkers market is segmented on the basis of:
Types
Oncology, Cardiovascular Diseases, Neurological Diseases
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Diagnostic and Research Laboratories, Hospitals
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche Diagnostics
- Myriad Genetics
- QIAGEN
- Thermo Fisher Scientific
- Bio-Rad Laboratories
Highlights of The Genomics Biomarkers Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oncology
- Cardiovascular Diseases
- Neurological Diseases
- By Application:
- Diagnostic and Research Laboratories
- Hospitals
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Genomics Biomarkers Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Genomics biomarkers are genetic markers that can be used to identify a person's risk for developing a particular disease or condition.
Some of the major companies in the genomics biomarkers market are Roche Diagnostics, Myriad Genetics, QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories.
The genomics biomarkers market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Genomics Biomarkers Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Genomics Biomarkers Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Genomics Biomarkers Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Genomics Biomarkers Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Genomics Biomarkers Market Size & Forecast, 2018-2028
4.5.1 Genomics Biomarkers Market Size and Y-o-Y Growth
4.5.2 Genomics Biomarkers Market Absolute $ Opportunity
Chapter 5 Global Genomics Biomarkers Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Genomics Biomarkers Market Size Forecast by Type
5.2.1 Oncology
5.2.2 Cardiovascular Diseases
5.2.3 Neurological Diseases
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Genomics Biomarkers Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Genomics Biomarkers Market Size Forecast by Applications
6.2.1 Diagnostic and Research Laboratories
6.2.2 Hospitals
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Genomics Biomarkers Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Genomics Biomarkers Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Genomics Biomarkers Analysis and Forecast
9.1 Introduction
9.2 North America Genomics Biomarkers Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Genomics Biomarkers Market Size Forecast by Type
9.6.1 Oncology
9.6.2 Cardiovascular Diseases
9.6.3 Neurological Diseases
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Genomics Biomarkers Market Size Forecast by Applications
9.10.1 Diagnostic and Research Laboratories
9.10.2 Hospitals
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Genomics Biomarkers Analysis and Forecast
10.1 Introduction
10.2 Europe Genomics Biomarkers Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Genomics Biomarkers Market Size Forecast by Type
10.6.1 Oncology
10.6.2 Cardiovascular Diseases
10.6.3 Neurological Diseases
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Genomics Biomarkers Market Size Forecast by Applications
10.10.1 Diagnostic and Research Laboratories
10.10.2 Hospitals
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Genomics Biomarkers Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Genomics Biomarkers Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Genomics Biomarkers Market Size Forecast by Type
11.6.1 Oncology
11.6.2 Cardiovascular Diseases
11.6.3 Neurological Diseases
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Genomics Biomarkers Market Size Forecast by Applications
11.10.1 Diagnostic and Research Laboratories
11.10.2 Hospitals
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Genomics Biomarkers Analysis and Forecast
12.1 Introduction
12.2 Latin America Genomics Biomarkers Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Genomics Biomarkers Market Size Forecast by Type
12.6.1 Oncology
12.6.2 Cardiovascular Diseases
12.6.3 Neurological Diseases
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Genomics Biomarkers Market Size Forecast by Applications
12.10.1 Diagnostic and Research Laboratories
12.10.2 Hospitals
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Genomics Biomarkers Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Genomics Biomarkers Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Genomics Biomarkers Market Size Forecast by Type
13.6.1 Oncology
13.6.2 Cardiovascular Diseases
13.6.3 Neurological Diseases
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Genomics Biomarkers Market Size Forecast by Applications
13.10.1 Diagnostic and Research Laboratories
13.10.2 Hospitals
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Genomics Biomarkers Market: Competitive Dashboard
14.2 Global Genomics Biomarkers Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche Diagnostics
14.3.2 Myriad Genetics
14.3.3 QIAGEN
14.3.4 Thermo Fisher Scientific
14.3.5 Bio-Rad Laboratories
